|
KMID : 0869620180350020177
|
|
Journal of Korean Society of Hospital Pharmacists
2018 Volume.35 No. 2 p.177 ~ p.183
|
|
|
Incidence and Risk Factors of the Infusion-Related Reactions in Breast Cancer Patients Receiving Trastuzumab
|
|
Jeong Ji-Hye
Kim Yoo-Jin
Yeo Mi-Jin
Park Ae-Ryoung
Kim Soon-Joo
Hwangbo Shin-Yi
La Hyen-O
|
|
|
Abstract
|
|
|
Background : Trastuzumab is a monoclonal antibody for use in the treatment of the human epidermal growth factor receptor-2 (HER2) often overexpressed in breast cancer. One of its common side effects of this therapy use is the infusion-related reactions. Conversely, it is noted that there are no guidelines for preventing these side effects in patients. In this study, we aimed to find grounds to support the safe use of trastuzumab based on an analysis of the incidence and risk factor of the infusion-related reactions in breast cancer patients receiving trastuzumab.
Methods : We evaluated the infusion-related reactions of the breast cancer patients receiving the first trastuzumab between Jan 1, 2014 and June 30, 2015. For the analysis of the risk factors, we collected the patient’s information retrospectively using the access to the patient’s secured electronic medical records.
Results : In this study, a total of 91 patients were evaluated, and the total number of trastuzumab administration was with 270 cases. The infusion-related reactions were identified in 18 patients and the incidence was recorded at 19.8%. All infusion-related reactions were occurred during the first dose. And the symptoms began in the average timeframe of 76.5 minutes after the administration. The incidence of the infusion-related reactions was 11.1% in patients receiving premedication, and 21.9% in the patients not receiving the premedication (p=0.31). Particularly speaking, the patients who were weighing more than 70kg had a significantly higher risk of infusion-related reactions, than the patients who were known to weighing less than 70kg (odds ratio 5.23; 95% CI, 1.32 - 20.67; P=0.01). And the higher patient's body mass index tended to occur more infusion-related reactions (odds ratio 1.15; 95% CI, 0.98 - 1.35; P=0.08).
Conclusion : Based on this result, in order to administer the trastuzumab safely, we suggest that the prevention guideline for the infusion-related reactions need to be utilized to consider the patient's body weight, and it is necessary to strengthen the monitoring to continue until the latter half of the drug therapy administration.
|
|
|
KEYWORD
|
|
|
rastuzumab, Infusion-related reactions, Breast cancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|